Genes differentially expressed in prostate cancer

被引:13
作者
Eder, IE [1 ]
Bektic, J [1 ]
Haag, P [1 ]
Bartsch, G [1 ]
Klocker, H [1 ]
机构
[1] Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria
关键词
D O I
10.1111/j.1464-410X.2004.04869.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Because of the heterogeneity of prostate cancer knowledge about the genes involved in prostate carcinogenesis is still very limited. Previously, the use of novel high-throughput technologies offered the possibility to investigate broad gene expression profiles and thus helped to improve understanding of the molecular basis of prostate disease. Many candidate genes have been identified so far which have a more or less strong effect on prostate cancer. This vast number of gene expression changes show that it is unlikely that only one gene promotes prostate cancer. Conversely, it seems more likely that a broad network of molecular changes is involved in the complex cascade of events which lead to tumour formation and progression, respectively. A few of these novel molecular targets are currently under clinical evaluation. This paper gives an overview of several interesting candidate genes which may be useful as improved biomarkers for diagnosis or as targets for developing novel treatment methods.
引用
收藏
页码:1151 / 1155
页数:5
相关论文
共 55 条
  • [1] Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo
    Baron, V
    De Gregorio, G
    Krones-Herzig, A
    Virolle, T
    Calogero, A
    Urcis, R
    Mercola, D
    [J]. ONCOGENE, 2003, 22 (27) : 4194 - 4204
  • [2] Growth factors and their receptors: New targets for prostate cancer therapy
    Barton, J
    Blackledge, G
    Wakeling, A
    [J]. UROLOGY, 2001, 58 (2A) : 114 - 122
  • [3] Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
  • [4] Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays
    Bubendorf, L
    Kolmer, M
    Kononen, J
    Koivisto, P
    Mousses, S
    Chen, YD
    Mahlamäki, E
    Schraml, P
    Moch, H
    Willi, N
    Elkahloun, AG
    Pretlow, TG
    Gasser, TC
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) : 1758 - 1764
  • [5] Bussemakers MJG, 1999, CANCER RES, V59, P5975
  • [6] Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer - Results from a pilot study
    Chakravarti, A
    Zehr, EM
    Zietman, AL
    Shipley, WU
    Goggins, WB
    Finkelstein, DM
    Young, RH
    Chang, EL
    Wu, CL
    [J]. UROLOGY, 2000, 55 (05) : 635 - 638
  • [7] Chi KN, 2001, CLIN CANCER RES, V7, P3920
  • [8] Expression profiling using cDNA microarrays
    Duggan, DJ
    Bittner, M
    Chen, YD
    Meltzer, P
    Trent, JM
    [J]. NATURE GENETICS, 1999, 21 (Suppl 1) : 10 - 14
  • [9] Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells
    Eder, IE
    Haag, P
    Basik, M
    Mousses, S
    Bektic, J
    Bartsch, G
    Klocker, H
    [J]. MOLECULAR CARCINOGENESIS, 2003, 37 (04) : 181 - 191
  • [10] Molecular biology of the androgen receptor: From molecular understanding to the clinic
    Eder, IE
    Culig, Z
    Putz, T
    Nessler-Menardi, C
    Bartsch, G
    Klocker, H
    [J]. EUROPEAN UROLOGY, 2001, 40 (03) : 241 - 251